OTCPK:RVAL.L

Stock Analysis Report

Executive Summary

REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications.

Snowflake

Fundamentals

Slightly overvalued with questionable track record.

Share Price & News

How has REVA Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

RVAL.L

-1.6%

US Medical Equipment

0.07%

US Market


1 Year Return

-99.5%

RVAL.L

13.8%

US Medical Equipment

8.9%

US Market

Return vs Industry: RVAL.L underperformed the US Medical Equipment industry which returned 13.8% over the past year.

Return vs Market: RVAL.L underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

RVAL.LIndustryMarket
7 Day0%-1.6%0.07%
30 Day0%-4.3%-0.3%
90 Dayn/a-4.3%-1.6%
1 Year-99.5%-99.5%14.7%13.8%11.3%8.9%
3 Yearn/a70.7%65.6%46.3%36.8%
5 Year-99.2%-99.2%117.3%93.5%62.1%44.3%

Price Volatility Vs. Market

How volatile is REVA Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is REVA Medical undervalued compared to its fair value and its price relative to the market?

0.025x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RVAL.L's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RVAL.L's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RVAL.L is good value based on its PE Ratio (0x) compared to the Medical Equipment industry average (41.8x).

PE vs Market: RVAL.L is good value based on its PE Ratio (0x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RVAL.L's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RVAL.L has negative assets, so we can't compare its PB Ratio to the US Medical Equipment industry average.


Next Steps

Future Growth

How is REVA Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as REVA Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has REVA Medical performed over the past 5 years?

-26.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RVAL.L has become profitable over the past 5 years, growing earnings by 0% per year.

Accelerating Growth: RVAL.L's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RVAL.L had negative earnings growth (-26.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.2%).


Return on Equity

High ROE: RVAL.L's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: RVAL.L has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: RVAL.L is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is REVA Medical's financial position?


Financial Position Analysis

Short Term Liabilities: RVAL.L has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RVAL.L has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RVAL.L has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RVAL.L's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: RVAL.L's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if RVAL.L's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: RVAL.L has a high level of physical assets or inventory.

Debt Coverage by Assets: RVAL.L has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Next Steps

Dividend

What is REVA Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate RVAL.L's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RVAL.L's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RVAL.L's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RVAL.L's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RVAL.L's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of REVA Medical's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

REVA Medical has no CEO, or we have no data on them.


Management Age and Tenure

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: RVAL.L's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

9.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: RVAL.L's board of directors are considered experienced (9.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jeff Anderson (52yo)

    President

    • Tenure: 0.6yrs
    • Compensation: US$741.20k
  • Paul Teirstein

    Key Consultant

    • Tenure: 0yrs
  • Alexandre Abizaid

    Co-Principal Investigator for Restore II Clinical Trial & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bob Stockman (65yo)

    Co-Founder & Director

    • Tenure: 20.8yrs
    • Compensation: US$117.82k
  • Moni Stein

    Key Consultant

    • Tenure: 0yrs
  • Joachim Kohn

    Key Consultant

    • Tenure: 0yrs
  • Cheryl Liberatore

    Director of Communications

    • Tenure: 0yrs
  • David Muller

    Co-Principal Investigator of Restore II Clinical Trial

    • Tenure: 7.1yrs
  • Leigh Elkolli (47yo)

    CFO, Principal Accounting Officer

    • Tenure: 0.8yrs
  • Jessica Earley

    Vice President of Operations & Product Development

    • Tenure: 0.8yrs

Board Members

  • Brian Dovey (77yo)

    Director

    • Tenure: 18.3yrs
    • Compensation: US$136.89k
  • Ray Larkin (70yo)

    Chairman of the Board

    • Tenure: 2.1yrs
    • Compensation: US$28.13k
  • Rob Thomas (74yo)

    Independent Non-Executive Director

    • Tenure: 9.3yrs
    • Compensation: US$130.32k
  • Gregg Stone (62yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Alexandre Abizaid

    Co-Principal Investigator for Restore II Clinical Trial & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bob Stockman (65yo)

    Co-Founder & Director

    • Tenure: 20.8yrs
    • Compensation: US$117.82k
  • Ross Breckenridge (49yo)

    Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: US$123.76k

Company Information

REVA Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: REVA Medical, Inc.
  • Ticker: RVAL.L
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$415.067k
  • Shares outstanding: 415.07m
  • Website: https://www.revamedical.com

Number of Employees


Location

  • REVA Medical, Inc.
  • 5751 Copley Drive
  • San Diego
  • California
  • 92111
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RVAL.LOTCPK (Pink Sheets LLC)YesCDI REPR 1/10 SHSUSUSDDec 2010

Biography

REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications. The company offers Fantom Encore, a bioreso ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:24
End of Day Share Price2019/10/16 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.